Navigation Links
Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Date:9/24/2007

Bristol-Myers Squibb to Advance Biologics Strategy Through Targeted

Biologics Acquisition

PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus(TM) Therapeutics announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins(TM). The acquisition of Adnexus will help advance Bristol-Myers Squibb's biologics strategy across multiple therapeutic areas and includes a Phase I oncology biologic, Angiocept(TM). Adnexus Therapeutics will become a subsidiary of Bristol-Myers Squibb and remain based in Waltham, Massachusetts.

Under the terms of the agreement Bristol-Myers Squibb will acquire all of Adnexus' issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction for a gross purchase price of $430 million, with the net purchase price being $415 million after deducting Adnexus' net cash balance at closing. In addition, there is an earn-out structure which could result in Bristol-Myers Squibb paying an additional amount of approximately $75 million, in three increments of approximately $25 million each, in the event certain development and regulatory milestones are achieved. The closing of the transaction is subject to customary regulatory approvals.

Adnectins are a proprietary class of targeted biologics developed by Adnexus. PROfusion(TM) is Adnexus' proprietary protein design engine, with which trillions of protein variations can be engineered at one time. Angiocept is an Adnectin designed to be an anti-angiogenic drug and is
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rockwell Automation to acquire British process-control firm
2. Madisons PunchStock acquired by Getty Images
3. Fiserv acquires crime management software firm
4. GenTel acquires GlaxoSmithKline chip platform
5. RedPrairie to acquire fleet management software firm
6. Tushaus Computer acquires managed service business
7. RedPrairie acquires Denver software company
8. Eagle Technology acquires some synergy
9. Brady Corp. acquires Korean counterpart
10. Canadian firm acquires Silicon Logic
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... YORK , Feb. 26, 2015 S&P ... Factual Stock Report coverage on MabVax Therapeutics Holdings ... (MBVX) is a clinical stage biotechnology company focused on ... unmet medical needs in the treatment of cancer. MabVax ... based on the protective immune responses generated by patients ...
(Date:2/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... develops and commercializes proprietary technologies and products for advanced ... for the fiscal first quarter ended December  31, 2014. ... dollars (CAD), unless otherwise stated. "During ... from our existing customers and add to our sales ...
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Feb. 27 Tengion Inc., a clinical,stage regenerative ... neo-vessels, announced today that it has appointed Jeff,Randall ... more than 25 years,experience as a senior- level ... to Tengion, including expertise in the healthcare, device,manufacturing ...
... CHARLESTON, S.C., Feb. 27 JSJ Pharmaceuticals ... new aesthetic division,Vitivia(TM). Vitivia(TM) will focus on ... of JSJ Pharmaceuticals in the development of,science-based, ... will be its Pro:Vitamin line.,Topical vitamins have ...
... February 27 Debiopharm Group,(Debiopharm), a global ... conditions and particularly oncology, today,announced the establishment ... Ecole,Polytechnique Federale de Lausanne (EPFL), focusing on ... 2.5 million endowment, the objective,of the chair ...
Cached Biology Technology:Tengion Appoints Jeff Randall to Board of Directors 2JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... York, NY) The Parkinson,s Disease Foundation (PDF) is pleased ... the potential of individualized stem cell therapy to treat ... research of Marina Emborg, M.D., Ph.D., and Su-Chun Zhang, ... This award was chosen as part of PDF,s ...
... DCGeorgetown University Medical Center and Oak Ridge ... the institutions that formalizes their research relationship ... in the areas of structural biology, systems ... The Comprehensive Research and Development Agreement ...
... 23, 2008 -- Eight Oak Ridge National Laboratory nanomanufacturing ... Department of Energy,s Industrial Technologies Program. The awards, ... $1.6 million to partners, are the result of a ... The awards are for the following projects: ...
Cached Biology News:Parkinson's Disease Foundation announces award of $150,000 2GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3ORNL nanotechnologies big winners in DOE call 2ORNL nanotechnologies big winners in DOE call 3
FRACTALKINE [Human] (Recombinant)...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
Argon Calibration Source...
SHEEP ANTI ESCHERICHIA COLI...
Biology Products: